Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers

• 2023

  Sign in to bookmark this resource.

  Sign in

---

Access Resources

• Job AidEN

About

This one-page infographic provides guidance on using nirsevimab (Beyfortus) to prevent severe RSV in infants and toddlers. It addresses high-risk conditions in children, as well as dosing information. Dosage depends on age, weight, and health conditions. Infants born during different months have specific guidelines for receiving doses. High-risk children aged 8-19 months entering their second RSV season need a 200mg dose before the season starts.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Cystic Fibrosis; Immunization Schedule; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Immunocompromised Host; Antibodies, Monoclonal, Humanized

Institutions: California Department of Public Health

---

More like this

Reporting Beyfortus to the Texas Immunization Registry: Data Quality Challenges 2024 · Texas Department of State Health Services Updated Interim Guidance for Health Departments on Testing and Reporting for Oropouche Virus Disease 2024 · Centers for Disease Control and Prevention (CDC) Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---